Oslo, Norway, 07 May 2025 Item 9 from the call to the annual general meeting will therefore be withdrawn. The Election Committee has received a request from Øystein Stray Spetalen that he does not want to be re- elected as a board member of Vistin Pharma ASA. The Election Committee has therefore assessed the consequences of this for the recommendation submitted 13 March 2025 to this year's annual general meeting. Øystein Spetalen was the only board member up for election, and it was recommended that he was ...

ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Lithium Argentina AG. (“Lithium Argentina” or the “Company”) (TSX: LAR) (NYSE: LAR) announces the release of its 2024 Sustainability Report, “Lithium With Purpose” (the “Report”). The Report highlights the Company’s overall Environmental, Social and Governance (“ESG”) progress from January 1 to December 31, 2024. Some of the highlights included in the Report included the following ESG related achievements at Cauchari-Olaroz: Completion of an updated materia ...

Geneva, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- QVault TPM Now Compliant with ML-DSA-87 and ML-KEM-1024, Leverages the Most Secure NIST-Standardized CRYSTALS-Dilithium and Kyber Algorithms for Quantum-Resistant ProtectionSEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced that its QVault Trusted Platform Module (TPM) is fully compliant with ML-DSA-87 and ML ...

Core Viewpoint - Theriva Biologics announced a public offering of up to 6,818,180 shares of common stock and warrants, aiming to raise approximately $7.5 million for working capital and R&D purposes [1][2]. Group 1: Offering Details - The offering price is set at $1.10 per share and accompanying warrant, with warrants exercisable immediately and expiring five years from issuance [1]. - The closing of the offering is expected on or about May 8, 2025, pending customary closing conditions [2]. - A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily be used for working capital and general corporate purposes, including research and development and manufacturing scale-up [2]. - The company may also consider using a portion of the proceeds for investments or acquisitions, although no commitments currently exist [2]. Group 3: Company Overview - Theriva Biologics is a clinical-stage company focused on developing therapeutics for cancer and related diseases, with a particular emphasis on high unmet medical needs [6]. - The company's lead candidates include VCN-01, SYN-004, and SYN-020, targeting various aspects of cancer treatment and microbiome protection [6].

About BRTX-100 BRTX-100, a novel cell-based therapeutic engineered to target areas of the body that have little blood flow, is BioRestorative's lead clinical candidate. The safety and efficacy of BRTX-100 in treating chronic lumbar disc disease ("cLDD") is being evaluated in a Phase 2, prospective, randomized, double-blinded and controlled study. The U.S. Food and Drug Administration ("FDA") recently granted Fast Track designation to the BRTX- 100 program for the treatment of cLDD, reflecting the positive p ...

April same-store sales increased 4.3% year-over-year* NEWARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- NRSInsights, a provider of sales data and analytics drawn from retail transactions processed through the National Retail Solutions (NRS) point-of-sale (POS) platform, today announced comparative retail same-store sales results for April 2025. As of April 30, 2025, the NRS retail network comprised approximately 35,600 active terminals nationwide, scanning purchases at approximately 31,000 independent retailer ...

Enrollment completed for the 6-week interim analysis with 24 of the 36 planned patients now enrolled Company on track to report interim biomarker data from the first 12 patients imminently Completion of patient enrollment and topline results expected Q3 2025 LA JOLLA, CA, May 07, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic a ...

Core Insights - Vicon Industries has secured a significant new order valued at approximately $1 million from a leading media organization in Saudi Arabia, marking a major milestone for its expansion into the Gulf region [1][4] - The order includes the NEXT Modular Sensor System, which features advanced starlight dome and bullet cameras, Valerus video management licenses, and high-capacity recording servers, all supported by Vicon's software and hardware platforms [2][4] - This deployment is Vicon's first major NEXT deployment in the Middle East, positioning the company as a preferred security technology partner in a rapidly growing market [4] Company Strategy - The contract reflects Cemtrex's continued execution of its 2025 growth strategy, which focuses on innovation, international expansion, and product leadership [4] - The deployment is scheduled to begin this quarter and supports critical broadcast infrastructure across multiple locations, with potential for future orders tied to ongoing infrastructure upgrades [3][4] Product Innovation - The NEXT platform integrates AI-enhanced imaging, real-time communication, and modular design into a rapid-deployment solution, highlighting the growing global demand for intelligent security systems [2][3]

Core Insights - PetMed Express, Inc. has announced a strategic partnership with Dutch to enhance its pet healthcare ecosystem by providing affordable and accessible veterinary care options [1][2] - The collaboration aims to address the nationwide veterinarian shortage, which has left over 129 million Americans without easy access to pet care [2][3] Company Overview - PetMed Express, Inc. is a leader in the consumer pet healthcare sector, offering a wide range of pharmaceuticals, generics, compounded medications, and OTC supplements through its online platforms [4] - The company operates under the brands PetMeds and PetCareRx, delivering services across all fifty states [4] Partnership Details - The partnership allows pet parents to sign up for a monthly Dutch membership, providing virtual access to veterinarians for 24/7 appointments in 34 states [2] - Dutch has completed nearly 700,000 visits and treats over 150 conditions, including flea and tick medication and treatments for allergies and joint pain [2] Industry Context - The 2025 State of Veterinary Care Report indicates that approximately 38% of the U.S. population lives in areas lacking adequate veterinary care, highlighting the need for telehealth solutions [3] - Dutch, launched in July 2021, connects licensed veterinarians with pet owners and has expanded its services to include prescription medications, addressing the critical vet shortage in the U.S. [5]

Dubai and Astana, May 07, 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator ("VEON" and together with its subsidiaries, the "Group"), announces that QazCode, its Kazakh software development company, has signed a Memorandum of Understanding (MoU) with Seekr, an artificial intelligence (AI) technology provider, to develop and implement AI-powered business-to-business (B2B) solutions across QazCode's operations. To accelerate its development of augmented intelligence solutions for use across all of VEO ...